Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A646587-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $210.90 | |
A646587-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $340.90 | |
A646587-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $680.90 | |
A646587-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,100.90 |
Synonyms | Azddmec|87190-79-2|CS-92|Az-Dcme|3'-Azido-2',3'-dideoxy-5-methylcytidine|Cytidine, 3'-azido-2',3'-dideoxy-5-methyl-|4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one|4-amino-1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahyd |
---|---|
Specifications & Purity | ≥98% |
Biochemical and Physiological Mechanisms | AzddMeC (CS-92) is an antiviral nucleoside analogue and a potent potent, selective and orally active HIV-1 reverse transcriptase and HIV-1 replication inhibitor. In HIV-1 -infected human PBM cells and HIV-1 -infected human macrophages, the EC 50 values of |
Storage Temp | Store at 2-8°C,Desiccated |
Shipped In | Wet ice |
Product Description | AzddMeC (CS-92) is an antiviral nucleoside analogue and a potent potent, selective and orally active HIV-1 reverse transcriptase and HIV-1 replication inhibitor. In HIV-1 -infected human PBM cells and HIV-1 -infected human macrophages, the EC 50 values of AzddMeC are 9 nM and 6 nM, respectively In Vitro AzddMeC (CS-92) is also effective against HIV-2 in lymphocytes. The replication of Friend murine virus is only weakly inhibited, and no effect is observed against HSV type 1 and type 2 and coxsackievirus B4. The interaction of the 5'-triphosphate of AzddMeC with HIV-1 reverse transcriptase indicated competitive inhibition (the inhibition constant, Kis, is 9.3 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The pharmacokinetics of AzddMeC are characterized following intravenous and oral administration of 60 mg/kg of the compound to male rhesus monkeys. 3'-azido-3'-deoxythymidine (AZT) is a major metabolite of AzddMeC in monkeys. AzddMeC concentrations in serum declined rapidly in a biexponential fashion with the terminal half-life ranging from 0.5 to 1.3 hr. Renal excretion of unchanged nucleoside and metabolic deamination yielding AZT are the primary routes of AzddMeC clearance. The oral bioavailability is 26%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:HIV-1 9 nM (EC 50 , Human PBM cells) HIV-1 6 nM (EC 50 , Human macrophages) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one |
---|---|
INCHI | InChI=1S/C10H14N6O3/c1-5-3-16(10(18)13-9(5)11)8-2-6(14-15-12)7(4-17)19-8/h3,6-8,17H,2,4H2,1H3,(H2,11,13,18)/t6-,7+,8+/m0/s1 |
InChi Key | GZSDAHQGNUAEBC-XLPZGREQSA-N |
Canonical SMILES | CC1=CN(C(=O)N=C1N)C2CC(C(O2)CO)N=[N+]=[N-] |
Isomeric SMILES | CC1=CN(C(=O)N=C1N)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-] |
Alternate CAS | 87190-79-2 |
PubChem CID | 64986 |
MeSH Entry Terms | 3'-azido-2',3'-dideoxy-5-methylcytidine;Az-dCME;AzddMeC;CS-92 |
Molecular Weight | 266.26 |
Enter Lot Number to search for COA:
Solubility | DMSO : 200 mg/mL (751.15 mM; Need ultrasonic) |
---|